Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Unloaded Rep. Jonathan L. Jackson

Representative Jonathan L. Jackson (D-Illinois) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on December 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on November 1st. The trade occurred in the Representative's "MORGAN STANLEY TRUST ACCOUNT" account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Amazon.com NASDAQ: AMZN on 11/27/2024.
• Sold $15,001 - $50,000 in shares of Applied Materials NASDAQ: AMAT on 11/27/2024.
• Sold $15,001 - $50,000 in shares of Regeneron Pharmaceuticals NASDAQ: REGN on 11/13/2024.
• Purchased $15,001 - $50,000 in shares of Church & Dwight NYSE: CHD on 11/13/2024.
• Purchased $15,001 - $50,000 in shares of Salesforce NYSE: CRM on 10/28/2024.
• Sold $15,001 - $50,000 in shares of ASML NASDAQ: ASML on 10/28/2024.
• Purchased $15,001 - $50,000 in shares of General Dynamics NYSE: GD on 9/24/2024.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 9/24/2024.
• Purchased $15,001 - $50,000 in shares of Aramark NYSE: ARMK on 9/19/2024.
• Sold $15,001 - $50,000 in shares of AES NYSE: AES on 9/19/2024.

Regeneron Pharmaceuticals Trading Down 1.3 %

Shares of REGN traded down $9.67 during mid-day trading on Friday, reaching $731.30. The company had a trading volume of 696,989 shares, compared to its average volume of 847,429. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $728.68 and a fifty-two week high of $1,211.20. The firm has a fifty day simple moving average of $849.77 and a 200-day simple moving average of $1,004.02. The stock has a market cap of $80.36 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Leerink Partners reiterated a "market perform" rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a "neutral" rating and a $895.00 price target on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Oppenheimer dropped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,099.90.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Finally, Family Firm Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois' 1st Congressional District. Jackson assumed office on January 3, 2023. Jackson's current term ends on January 3, 2025. Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois' 1st Congressional District. Jackson declared candidacy for the 2024 election. Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson's career experience includes working as an investment analyst and an entrepreneur.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.